Nicholas Ball

NERx Biosciences, Inc. engages in the discovery and development of targeted therapeutics for cancer. The firm specializes in early development of novel biopharmaceutical compounds. It focuses on new generation of cancer drugs that target specific cellular processes not currently being exploited as cancer therapies. The company was founded by John Turchi and Robert Feltgen in 2009 and is headquartered in Indianapolis, IN.

NERx Biosciences, Inc. engages in the discovery and development of targeted therapeutics for cancer. The firm specializes in early development of novel biopharmaceutical compounds. It focuses on new generation of cancer drugs that target specific cellular processes not currently being exploited as cancer therapies. The company was founded by John Turchi and Robert Feltgen in 2009 and is headquartered in Indianapolis, IN.

NERx Biosciences, Inc. engages in the discovery and development of targeted therapeutics for cancer. The firm specializes in early development of novel biopharmaceutical compounds. It focuses on new generation of cancer drugs that target specific cellular processes not currently being exploited as cancer therapies. The company was founded by John Turchi and Robert Feltgen in 2009 and is headquartered in Indianapolis, IN.